Prof Cristiana Sessa speaks to ecancer at the BGICC 2020 conference in Cairo, Egypt about the recent data which justify the clinical developments seen in ovarian cancer.

She discusses the two new classes of drug used to treat this disease which include PARP inhibitors and immunotherapy.